A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.
一项机会窗口试验揭示了复发性胶质母细胞瘤患者对纳夫特马德林产生反应和耐药性的机制
期刊:Science Translational Medicine
影响因子:14.6
doi:10.1126/scitranslmed.adn6274
Rendo Veronica, Lee Eudocia Q, Bossi Connor, Khuu Nicholas, Rudek Michelle A, Pal Sangita, Azazmeh Narmen, Rashid Rumana, Lin Jia-Ren, Cusick Margaret, Reynolds Abigail R N, Fassinou Auriole C R, Ayoub Georges, Malinowski Seth, Lapinskas Emily, Pisano William, Jeang John, Stopka Sylwia A, Regan Michael S, Spetz Johan, Desai Arati, Lieberman Frank, Palanichamy Kamalakannan, Fisher Joy D, Pelton Kristine, Huang Raymond Y, Sarosiek Kristopher A, Nabors Louis B, Holdhoff Matthias, Danda Neeraja, Strowd Roy, Desideri Serena, Walbert Tobias, Ye Xiaobu, Chakravarti Arnab, Sorger Peter K, Santagata Sandro, Agar Nathalie Y R, Grossman Stuart A, Alexander Brian M, Wen Patrick Y, Ligon Keith L, Beroukhim Rameen
